scholarly journals The reliability and ralidity of the European League Against Rheumatism Sjögren Syndrome Patient Reported Index in patients with primary Sjögren syndrome: A Turkish version study

2020 ◽  
Vol 36 (3) ◽  
pp. 317-325
Author(s):  
Elif Gür Kabul ◽  
Aylin Keskin ◽  
Pervin Demir ◽  
Bilge Başakcı Çalık ◽  
Veli Çobankara
Keyword(s):  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Syndrome Patient ◽  
Turkish Version ◽  
Primary Sjögren Syndrome ◽  
European League Against Rheumatism ◽  
Patient Reported ◽  
European League

Axial Articular Manifestations in Primary Sjögren Syndrome: Have We Been Missing Spondyloarthritis for All This Time?

2021 ◽  
pp. jrheum.201175
Author(s):  
Robert I. Fox ◽  
Carla M. Fox
Keyword(s):  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Retrospective Evaluation ◽  
Prolonged Time ◽  
Primary Sjögren Syndrome ◽  
American College Of Rheumatology ◽  
Time Period ◽  
European League Against Rheumatism ◽  
European League

Jarrot and colleagues1 present a retrospective evaluation of 148 patients with primary Sjögren syndrome (SS) who fulfilled the American College of Rheumatology/European League Against Rheumatism criteria for SS, and also fulfilled the criteria for spondyloarthritis (SpA). The patients were largely from Marseille, France, and were followed over a prolonged time period.

scholarly journals Abdominal symptoms during Sjogren’s syndrome: a pilot study

2021 ◽  
Vol 61 (1) ◽  
Author(s):  
Simon Parreau ◽  
Jérémie Jacques ◽  
Stéphanie Dumonteil ◽  
Sylvain. Palat ◽  
Sophie Geyl ◽  
...  
Keyword(s):  
Symptom Score ◽  
Activity Index ◽  
Central Nervous System Involvement ◽  
Disease Activity Index ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Primary Sjögren Syndrome ◽  
Abdominal Symptoms ◽  
Patient Reported ◽  
Therapeutic Recommendation

Abstract Background Abdominal symptoms in patients with primary Sjögren syndrome (pSS) are poorly documented. The objective of the study was to describe the abdominal symptoms of patients with pSS and to assess their association with characteristics of the disease. Methods One hundred and fifty patients with pSS were evaluated using a composite global symptom score for abdominal symptoms and their severity. Data concerning the clinical and biological characteristics of pSS and abdominal disorders were also collected. Results Of the patients with pSS, 95% suffered from abdominal symptoms (median global symptom score 7.5 ± 5.5 points out of 30). More than half of the patients experienced abdominal tension (68%), upper abdominal pain (54%), abdominal discomfort (58%) and/or constipation (54%). Regarding the pSS activity, in relation to European League Against Rheumatism (EULAR) Sjögren syndrome disease activity index score items, general and central nervous system involvement wereassociated with a high global symptom score. The EULAR Sjogren Syndrome Patient Reported Index (ESSPRI) symptom score was positively correlated with the global symptom score (p < 0.01). Multivariate analysis showed a significant association between a high global symptom score and SSA seronegativity, gastroparesis, and ESSPRI score (p < 0.01 for each). Conclusions The majority of patients with pSS suffered abdominal symptoms. There is currently no therapeutic recommendation because of the lack of information on the underlying pathophysiological mechanisms. Trial registration NCT03157011. Date of registration: July 17, 2017.

scholarly journals PULMONARY NON-HODGKIN LYMPHOMA IN A PRIMARY SJÖGREN SYNDROME PATIENT

2016 ◽  
Vol 25 (2) ◽  
pp. 95-99
Author(s):  
Claudia Deaconu ◽  
◽  
Ruxandra Ionescu ◽  
Daniela Opris ◽  
◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Membranous Glomerulonephritis ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Syndrome Patient ◽  
Non Hodgkin Lymphoma ◽  
Primary Sjögren Syndrome ◽  
Pulmonary Lymphoma ◽  
Autoimmune Condition ◽  
Lymphocytic Infiltrates

Sjögren syndrome (SS) is a chronic autoimmune condition that mainly targets exocrine glands where it produces lymphocytic infiltrates. The clinical display varies in severity and can include malignancy association such as non-Hodgkin lymphoma. Its incidence ranges from 5 to 8%, while the risk of occurrence is 16 to 44 times higher. This article aims to describe the evolution of a patient with primary SS who developed pulmonary lymphoma for which she received Rituximab as part of the oncological therapeutic scheme. During the course of the disease she developed membranous glomerulonephritis, rarely described in these patients and low complement levels cited as predictive factor for lymphoproliferation.

Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome

2017 ◽  
Vol 44 (3) ◽  
pp. 292-296 ◽  
Author(s):  
Rada V. Moerman ◽  
Suzanne Arends ◽  
Petra M. Meiners ◽  
Arjan Vissink ◽  
Frederik K.L. Spijkervet ◽  
...  
Keyword(s):  
Disease Activity ◽  
Disease Activity Score ◽  
Activity Index ◽  
Disease Activity Index ◽  
Sjögren Syndrome ◽  
Joint Disease ◽  
Sjogren Syndrome ◽  
Reactive Protein ◽  
Primary Sjögren Syndrome ◽  
European League Against Rheumatism

Objective.We used the 28-joint Disease Activity Score (DAS28) and the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI) articular domain to assess the effect of rituximab (RTX) and abatacept (ABA) on articular involvement in primary Sjögren syndrome (pSS).Methods.Patients with pSS treated with RTX (n = 18) or ABA (n = 13) and having a DAS28 erythrocyte sedimentation rate (ESR)/C-reactive protein (CRP) level ≥ 3.2 at baseline were selected. Generalized estimating equations were used to analyze the DAS28 and ESSDAI articular domain over time.Results.In the RTX group, DAS28-ESR/CRP decreased significantly up to 48 weeks. In the ABA group, DAS28-ESR/CRP decreased significantly up to 24 weeks. DAS28 correlated significantly with ESSDAI articular domain.Conclusion.DAS28 is useful to evaluate the effect of biologicals on articular involvement in patients with pSS.

Cryoglobulinemia in Sjögren Syndrome: A Disease Subset that Links Higher Systemic Disease Activity, Autoimmunity, and Local B Cell Proliferation in Mucosa-associated Lymphoid Tissue

2017 ◽  
Vol 44 (8) ◽  
pp. 1179-1183 ◽  
Author(s):  
Luca Quartuccio ◽  
Chiara Baldini ◽  
Roberta Priori ◽  
Elena Bartoloni ◽  
Francesco Carubbi ◽  
...  
Keyword(s):  
Disease Activity ◽  
Activity Index ◽  
Systemic Disease ◽  
Disease Activity Index ◽  
Sjögren Syndrome ◽  
Sjogren Syndrome ◽  
Systemic Activity ◽  
Primary Sjögren Syndrome ◽  
System P ◽  
European League Against Rheumatism

Objective.To compare systemic disease activity by validated tools, i.e., the European League Against Rheumatism Sjögren Syndrome Disease Activity Index (ESSDAI) and the Clinical ESSDAI (ClinESSDAI) scores, between primary Sjögren syndrome (pSS) with positive serum cryoglobulins and pSS without serum cryoglobulins.Methods.There were 825 consecutive patients with pSS who were retrospectively evaluated.Results.The ESSDAI and the ClinESSDAI scores were significantly higher in cryoglobulin-positive patients (p < 0.0001, for both scores). Cryoglobulinemia was significantly associated with these domains: constitutional (p = 0.003), lymphadenopathy (p = 0.007), glandular (p = 0.0002), cutaneous (p < 0.0001), peripheral nervous system (p < 0.0001), hematological (p = 0.004), and biological (p < 0.0001).Conclusion.Cryoglobulin-positive patients show the highest systemic activity in pSS.

Sign in / Sign up

Export Citation Format

Share Document